Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1169

1.

Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.

Garikipati V, Toops DS, Fang Q.

Curr Med Res Opin. 2008 Jul;24(7):1869-76. doi: 10.1185/03007990802122735 .

PMID:
18593524
2.

A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.

Marcelín-Jiménez G, Angeles-Moreno AP, Contreras-Zavala L, Morales-Martínez M, Rivera-Espinosa L.

Clin Ther. 2009 Sep;31(9):2002-11. doi: 10.1016/j.clinthera.2009.09.016.

PMID:
19843490
4.

Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers.

Dutta S, Zhang Y, Lee LL, O'Dea R.

Biopharm Drug Dispos. 2004 Nov;25(8):353-7.

PMID:
15378556
5.

Bioequivalence of single and multiple doses of venlafaxine extended-release tablets and capsules in the fasted and fed states: four open-label, randomized crossover trials in healthy volunteers.

Wright CW, Aikman MS, Werts E, Seabolt J, Haeusler JM.

Clin Ther. 2009 Nov;31(11):2722-34. doi: 10.1016/j.clinthera.2009.11.025.

PMID:
20110014
6.
8.
9.

Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.

Palma-Aguirre JA, Villalpando-Hernández J, Novoa-Heckel G, Oliva I, Cariño L, López-Bojórquez E, Burke-Fraga V, Namur S, González-de la Parra M.

Clin Ther. 2009 Feb;31(2):399-410. doi: 10.1016/j.clinthera.2009.02.002.

PMID:
19302912
10.
11.

Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.

Dutta S, Reed RC, O'Dea RF.

Ann Pharmacother. 2006 Apr;40(4):619-25. Epub 2006 Mar 28.

PMID:
16569797
12.
13.

Results of a single-center, single-dose, randomized-sequence, open-label, two-way crossover bioequivalence study of two formulations of valsartan 160-mg tablets in healthy volunteers under fasting conditions.

Spínola AC, Almeida S, Filipe A, Neves R, Trabelsi F, Farré A.

Clin Ther. 2009 Sep;31(9):1992-2001. doi: 10.1016/j.clinthera.2009.09.002.

PMID:
19843489
14.
15.
16.
17.

Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.

Wangemann M, Retzow A, Vens-Cappell B.

Int J Clin Pharmacol Ther. 1999 Feb;37(2):100-8.

PMID:
10082174
18.

Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers.

Fontes-Ribeiro C, Macedo T, Nunes T, Neta C, Vasconcelos T, Cerdeira R, Lima R, Rocha JF, Falcão A, Almeida L, Soares-da-Silva P.

Drugs R D. 2008;9(6):447-54. doi: 10.2165/0126839-200809060-00007.

PMID:
18989993
20.

Supplemental Content

Support Center